Evaluation of aprepitant and fosaprepitant in pediatric patients

• DOI: 10.1111/ped.13780
• Publication Date: 2019-01-08T22:28:54Z
• Authors: Yoshimasa Saito; Tadashi Kumamoto; Takamichi Arima; Nami Shirakawa; Sae Ishimaru; Tomoko Sonoda; Miho Nakajima; Masanaka Sugiyama; Ayumu Arakawa; Hironobu Hashimoto; Yoshinori Makino; Chitose Ogawa; Masakazu Yamaguchi
• Keywords: Aprepitant; Clinical endpoint

Abstract Background Single‐dose i.v. fosaprepitant has been approved as an alternative to 3 day oral aprepitant, a neurokinin‐1 receptor antagonist, and improves prevention of chemotherapy‐induced nausea vomiting ( CINV ). Because shown similar efficacy aprepitant in adult patients only, this study compared the safety pediatric patients. Methods Children younger than 18 years who received or manage between January 2015 March 2018 at National Cancer Center Hospital (Tokyo) were recruited study. The primary endpoint was complete response CR ; no vomiting/rescue medication) 0 120 h after start chemotherapy. Secondary endpoints based on frequency severe adverse events, evaluation patient characteristics risk factors (effect age sex). Results A total 125 chemotherapy cycles evaluated. In group, observed 36 80 treatment (45.0%), whereas it 19 45 (42.2%; P = 0.852). No treatment‐related events either group. number non‐ greater that aged 6–14 years. difference rate male female not statistically significant (47.1% vs 40.0%, respectively; 0.471). Conclusions Aprepitant safely used may be equally useful for receiving highly emetogenic associated with age.